Managing patients treated with bevacizumab combination therapy. - Wikidata - wikimedia - TriplyDB

Managing patients treated with bevacizumab combination therapy.

Managing patients treated with bevacizumab combination therapy.

http://www.wikidata.org/entity/Q36319038

about

Targeting angiogenesis in gynecologic cancers Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Bevacizumab in ovarian cancer: A critical review of phase III studies Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis Venous thromboembolism in malignant gliomas Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.Antivascular therapy for epithelial ovarian cancer.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study Tumor growth and angiogenesis is impaired in CIB1 knockout mice Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.The current status of emergency operations at a high-volume cancer center.Renal involvement in preeclampsia: similarities to VEGF ablation therapy A pilot study of bevacizumab and interferon-α2b in ocular melanoma.Rejuvenation: an integrated approach to regenerative medicine.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library.Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.The risk for anemia with targeted therapies for solid tumors Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy Emerging treatments for choroidal metastases.Mechanisms of adverse effects of anti-VEGF therapy for cancer.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Bevacizumab in the management of solid tumors.Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing.Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

P2860

Q26824766-60C2D9E5-94D4-4E12-BCB2-313BCF2FA44C Q28066747-AABFFB23-73F5-4EE2-A586-771E88326781 Q28076188-38EDECDB-9DC8-4888-A1BB-5C8E86DB0709 Q28534015-FF6E9B0E-1F3D-489A-9F59-0C6A5AC63F30 Q30436810-72A4930D-6291-4C43-8285-7676CC7805AF Q30440705-A2556163-C6D0-4E08-857D-A13C05A0BCF5 Q31152878-29CE9798-B8C1-4EBF-84B2-FFB0721D6E3F Q33428049-7EE84399-F838-4DA6-9595-CB0DF0D3C671 Q33583598-B8F4BDA1-B973-483C-B6BF-9A65D4133FCC Q33698419-51C755D5-1475-4B8A-AFB1-F0E10288C455 Q33795198-5B86AF01-6F02-4911-9267-CDA285D825C6 Q33909734-46A5BF1F-19CE-4A3D-8ED9-2D3D8CEF2B0D Q33990959-25EB9B18-8DA4-466F-B3BE-BCF17B03A3C9 Q34138822-67DA04D6-3E4B-441F-AB9F-DEE6697D92BF Q34206792-ED27EB5C-4194-49E7-AAD5-15B6B2E26372 Q34267451-B49C2B91-AAA9-4CFA-8226-6AE2A110A696 Q34346463-591E84FA-EDF1-4F28-93E0-43A734CF8DCB Q34623672-302889EB-2A61-4650-A73A-B8546EEE1416 Q34735646-304BC1D1-5315-4DB9-B213-A3B863D99B13 Q34961777-D3A7D13E-F3DA-4470-9754-657DC211108D Q35222931-86379963-5490-4B56-A023-D969C0F5EAAC Q35419004-457F324C-1547-4E48-B429-BE605E22AF2B Q35545895-23CFF54C-0A4E-4855-B6EC-099100B709F4 Q35584543-69F3E206-83B0-4496-A50A-BC538864D5A6 Q35585178-A0725D85-1B30-42DF-86D5-D58A97189DCA Q35703718-5E5DC10C-934D-40D5-A908-747025EAEDA1 Q35750289-CFD38FE0-EFFF-4790-AC6E-959C48797DA2 Q35989994-7F129A54-2B30-4D1E-87E9-E03E06D4DAE0 Q36105850-40B70400-3B96-497D-BD3E-D271ED8C1C20 Q36318627-47D10EA7-EC85-441C-A0FC-6867DFD24161 Q36519807-D46A5F26-6EC2-4A3F-B045-906DB62FE62D Q36609627-8BB5AD10-4908-45BA-AE67-88A093A442F2 Q36787777-DDEF844D-39B2-477E-A1BD-2FF06FCEB38D Q36788459-CF7428C4-A4AD-447E-822C-437AE3879E12 Q36816535-0409B8A6-3783-4500-B869-F98D9F0A781A Q37179782-BDCD9842-AF17-4581-AB53-B66ECC2484C8 Q37665798-F000F384-75C5-4106-B0D6-E432CC8F9F96 Q37692420-30E9DC78-0EBA-438C-ABB0-B11AC39BAAAB Q37698956-84B4FFE6-B45D-4BB7-9192-B6CD4636DC79 Q37718401-3666F76E-13A5-43E9-8DED-EE434CF986B9

P2860

Managing patients treated with bevacizumab combination therapy.

http://www.wikidata.org/entity/Q36319038

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Managing patients treated with bevacizumab combination therapy.

@ast

Managing patients treated with bevacizumab combination therapy.

@en

type

label

Managing patients treated with bevacizumab combination therapy.

@ast

Managing patients treated with bevacizumab combination therapy.

@en

prefLabel

Managing patients treated with bevacizumab combination therapy.

@ast

Managing patients treated with bevacizumab combination therapy.

@en

P1433

Q36319038-AD674C95-655A-461E-B9E9-402A39330EC4

P1476

Q36319038-27419502-1808-47C5-83FB-4E294BC1F27A

P2093

Q36319038-B4A8AEDA-5AC6-4F39-BB0D-6E8CD4B27ECC

P2860

Q36319038-2009D198-B069-43CE-A4AC-B4D7ACF0C646

Q36319038-31D7300A-6C28-46BC-B6BF-5F11098272F3

Q36319038-68B3E937-38F1-4459-BF05-6E8CCDB3FB96

Q36319038-83D403CB-3F6A-4BAC-A9C0-3D50A5E93915

Q36319038-9D819FD4-0B32-420D-8E91-7168B3447A7E

P304

Q36319038-B9FF424E-7BE9-445A-A62A-C2D46B071F24

P31

Q36319038-73A69160-06EF-4877-ADC8-0B317A25C1AF

P356

Q36319038-BD294C27-F183-40C6-A5FD-D96A560CB326

P478

Q36319038-A127F087-5F30-4262-B6DA-FE5BA9AD452E

P50

Q36319038-2E5871DD-8AE8-4B27-9892-DCB0AC7D45B8

P577

Q36319038-8DE2E5FC-65DB-42DE-99E7-16F864372D4F

P698

Q36319038-5C3FE81A-5ABE-4238-B320-0F4CB801B0C8

P921

Q36319038-8C3DB738-B6F9-44EC-AC1B-2985D6AF63D3

P356

P1433

P1476

Managing patients treated with bevacizumab combination therapy

@en

P2093

Michael S Gordon

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

P304

25-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000088481

http://www.w3.org/2001/XMLSchema#string

P478

69 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

P577

2005-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16301833

http://www.w3.org/2001/XMLSchema#string

P921